Expand SPRO Menu
SPRO MENU

SPRO Latest Press Releases

-- August 12, 2026 --

Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update Globe Newswire 4:01 PM

-- August 5, 2026 --

Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:05 PM

-- August 4, 2026 --

Spero Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026 Globe Newswire 4:01 PM

-- July 27, 2026 --

Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer Globe Newswire 8:00 AM

-- July 14, 2026 --

Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties Globe Newswire 6:02 AM
Innovent Biologics and Spero Therapeutics Announce Exclusive License for IBI355 (SP001), a Phase 2-Ready Third-Generation Anti-CD40L Antibody PRNewswire 6:00 AM
Spero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third-Generation Anti-CD40L Antibody Globe Newswire 6:00 AM

-- July 8, 2026 --

Avacta Appoints Healthcare Executive Patrick Vink as Deputy Chairman of the Board of Directors Globe Newswire 2:00 AM

-- June 29, 2026 --

Kailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer Globe Newswire 7:30 AM

-- June 17, 2026 --

Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs) Business Wire 4:21 PM
Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs) Globe Newswire 12:36 PM

-- May 28, 2026 --

Compass Pathways Elects Kathleen Tregoning to Board of Directors Business Wire 6:30 AM

-- May 13, 2026 --

Spero Therapeutics Announces First Quarter 2026 Operating Results and Provides Business Update Globe Newswire 4:05 PM

-- May 5, 2026 --

Spero Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026 Globe Newswire 4:05 PM

-- March 26, 2026 --

Spero Therapeutics Announces Fourth Quarter and Full Year 2025 Operating Results and Provides a Business Update Globe Newswire 4:05 PM

-- March 18, 2026 --

Spero Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 26, 2026 Globe Newswire 4:05 PM
Market Data Delayed 15 Minutes